References
- Chisholm P. L., Williams C. A., Jones W. E., Majeau G. R., Oleson F. B., Burrus‐Fischer B., et al. The effects of an immunomodulatory LFA3‐IgG1 fusion protein on nonhuman primates. Ther Immunol 1994; 1: 205–16
- Ellis C. N., Krueger G. G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248–55
- Kraan M. C., van Kuijk A. W. R., Dinant H. J., Goedkoop A. Y., Smeets T. J. M., de Rie M. A., et al. Alefacept treatment in psoriatic arthritis – Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46: 2776–84
- Krueger G. G., Lebwohl M., Griffiths C. E. M., Dinant H. J., Goedkoop A. Y. Alefacept (LFA‐3/IgG(1)) selectively targets CD45RO(+) T cells, producing durable improvements in psoriasis and psoriatic arthritis. Allergy 2002; 57: 61–2
- Krueger G. G., Papp K. A., Stough D. B., Loven K. H., Gulliver W. P., Ellis C. N. A randomized, double‐blind, placebo‐controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plague psoriasis. J Am Acad Dermatol 2002; 47: 821–33
- Gottlieb A. B. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004; 8: 14–19
- Lowe N. J., Gonzalez J., Bagel J., Caro I., Ellis C. N., Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003; 42: 224–30
- Ortonne J. P. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 12–16
- Korman N. J., Moul D. K. Alefacept for the treatment of psoriasis: A review of the current literature and practical suggestions for everyday clinical use. Semin Cutan Med Surg 2005; 24: 10–18
- Lebwohl M., Christophers E., Langley R., Ortonne J. P., Roberts J., Griffiths C. E. M. An international, randomized, double‐blind, placebo‐controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719–27
- Ortonne J. P., Khemis A., Koo J. Y., Choi J. An open‐label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 556–63
- Scheinfeld N. Therapy‐resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J 2005; 11: 7
- Cather J. C., Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg 2005; 24: 37–45
- Amevive (alefacept) Package Insert. Biogen Inc., Cambridge, MA, August 2004
- Krueger G. G., Ellis C. N. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148: 784–8
- Krueger G. G., van de Kerkhof P. C. Safety of multiple courses of alefacept in combination with other psoriasis therapies: A study that reflects the clinical practice setting. J Am Acad Dermatol 2004; 50: P152, (Abstract P591)